Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.

Dermatol Ther (Heidelb) · 2016 · PMC4906115 · PMID 27221323

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The pooled data beyond 12 weeks for all three trials revealed a positive trend in results, with 64% of the overall patients in the brodalumab 210 mg Q2W pooled group and 45.9% in the brodalumab 140 mg Q2W pooled group achieving sPGA 0 or 1 at 52 weeks.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.